Mandate

Vinge advises IK Investment Partners in connection with investment in the Ramudden group

April 09, 2014

Vinge is advising IK Investment Partner’s IK VII fund in connection with its investment in the Ramudden group. Ramudden provides equipment and services for increasing traffic safety in conjunction with road works and on roadways in Sweden, Norway and Finland. The company provides turnkey solutions and partial solutions for traffic facilities including traffic facilities plans, training, road closures, protection barriers, signs, traffic signals, monitoring, speed ramps and service. The transaction is conditional upon approval by the relevant competition authorities and other customary conditions to closing.

Vinge’s team consists of partner Jonas Bergström together with, among others, associates Karl Hahtovirta, Filip Öhrner, Anna Lönergan and Sara Strandberg. Partner Kristian Hugmark and associate Ina Lunneryd are advising on competition law matters.   

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026